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INTRODUCTION
In clinical trials comparing inhaled (Exubera; [insulin human rDNA origin] inhalation powder) 1 with s.c. administered (Humulin R; Eli Lilly and Company, Indianapolis, IN) insulin. Exubera reduced postprandial glucose levels at least as effectively as Humulin in the first 3-h, while maintaining lower glucose concentrations compared with Humulin during the fourth and fifth hour following meal consumption (Skyler et al., 2005) . Remarkably, fasting plasma glucose levels also were reduced by as much as 40 mg/dl compared with s.c. insulin in patients administered insulin by inhalation, whether as dry powder (Skyler et al., 2005; Garg et al., 2006; Hollander et al., 2004; Quattrin et al., 2004) or liquid (Hermansen et al., 2004) formulations. Thus, insulin delivery to the lungs may help to reduce insulin needs for insulin-dependent patients, especially overnight. In addition, inhaled insulin is also associated with less weight gain compared with s.c. insulin, which may directly result from reduced nocturnal insulin requirements (Hollander et al., 2007) .
We previously conducted a series of studies in dogs to investigate the specific gluco-metabolic effects of insulin delivered by inhalation compared with pharmacokinetically matched intravenous (i.v.) (Edgerton et al., 2005 ; Edgerton et al., 2006a) or s.c. administration (Cherrington et al., 2004; Edgerton et al., 2006b ). While these experiments confirmed the association of enhanced glucose clearance with the inhalation of insulin, they were limited to 4-h duration, and plasma insulin levels were allowed to fall to near zero after 3-h.
The aim of the present study was to determine the 8-h time course of the increase in non-hepatic glucose uptake (non-HGU) associated with inhaled insulin when This article has not been copyedited and formatted. The final version may differ from this version.
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Downloaded from compared with that observed with i.v. insulin. In addition, we explored a possible causal mechanism of this effect by measuring pulmonary angiotensin-converting enzyme (ACE) activity in response to insulin inhalation.
METHODS
Experiments were conducted at the Lovelace Respiratory Research Institute (Albuquerque, NM) on 18-healthy, conscious, 18-h fasted female beagle dogs (8-13 kg).
Prior to the study, the dogs were fed a standard chow diet (Teklad 25% Mini Lab Dog On the day of exposure, all dogs were anesthetized. The dogs were given 0.2 ml of acepromazine s.c.; approximately 15 min later, 5% isofluorane was administered by inhalation using a mask until palpebral and pedal reflexes disappeared. The dogs were then intubated with an endotracheal tube and anesthesia was maintained with 1−2% isofluorane in oxygen. Three i.v. catheters (Terumo Medical Corporation, Somerset, NJ) were placed into the cephalic and/or saphenous veins to allow infusion of insulin, somatostatin, and glucagon. Insulin was then administered either by inhalation or i.v.
infusion.
Exubera is a dry powder human insulin of recombinant origin specially formulated for intrapulmonary administration. This insulin is packaged in a foil blister pack, with each blister containing 1.0 mg of human insulin. Humulin R, which is a recombinant human insulin, was used for i.v. infusion. It is assumed that the biological activity of insulin in both preparations was identical.
In the inhalation (INH) group, at baseline (t = 0 min) dogs inhaled the content of one blister of insulin using a modified P2.3 device (Nektar Therapeutics), as previously described (Edgerton et al., 2005) . No adverse clinical signs related to the inhalation of insulin were observed during the study. To prevent insulin deficiency following the washout of inhaled insulin, i.v. insulin was infused in the INH group between 95 and 485 min (Table 1 ). In the i.v. group (IV), after sham inhalation exposure, Humulin R diluted in normal saline (0.9% NaCl, Baxter Healthcare Corporation) with added plasma (3:100 ml) was infused into the IVC, using an algorithm designed to match the arterial plasma insulin kinetic profile of the INH group (Table 2) . Thus, during the first several hours of the study, insulin infusion was used in the IV group to match the insulin kinetics of the peptide, using immunoassay procedures. Blood for measurement of bradykinin (BK) and bradykinin 1-5 (BK1-5) was drawn into cold anhydrous ethanol. BK was assayed using a BK ELISA kit (S-1135; Bachem, San Carlos, CA), and BK1-5 was determined using a dual-isotope dilution mass spectrometric assay as described previously (Murphey et al., 2001 ). Blood for measuring angiotensin I (ATI) and angiotensin II ( 
RESULTS
Arterial plasma insulin levels peaked in 15 min at 92 ± 10 and 91 ± 13 µU/ml in the INH and IV groups, respectively, and reached a plateau of 18 ± 1 µU/ml by 2-h (Fig.   1A ). Hepatic sinusoidal plasma insulin levels peaked at 20 min at 69 ± 7 and 70 ± 11
This article has not been copyedited and formatted. The final version may differ from this version. 1B) and reached a plateau of 14 ± 1 µU/ml by 2-h. The total 485-min AUCs for arterial insulin were 12,098 ± 927 and 11,790 ± 1,010 µU/ml, in the INH and IV groups, respectively. Thus, the insulin concentrations and kinetic profiles were accurately matched between groups.
Arterial C-peptide levels dropped rapidly (<30 min) in both groups to concentrations near the level of detection of the assay (0.05 ng/ml) after initiation of somatostatin infusion, indicating that endogenous insulin secretion was quickly and effectively suppressed (Table 3 ). The arterial glucagon levels were close to basal and remained equivalent in the two groups throughout the experiment (Table 3) . Arterial plasma cortisol levels, an index of stress, were also not different between groups (Table   3 ).
The arterial plasma glucose levels increased from basal to 164 ± 2 mg/dl and 162 ± 2 mg/dl in the INH and IV groups, respectively ( Fig. 2A) , as a result of portal (4 mg/kg/min) and peripheral (variable rate) glucose infusion. Despite matched plasma insulin and glucose levels, the peripheral glucose infusion rate (peGIR) was greater following inhalation, peaking at 16.2 ± 3.1 vs. 12.0 ± 1.4 mg/kg/min at 80 min ( Fig. 2B; p < 0.05). Between 35 and 185 min the peGIR AUCs were 1,837 ± 352 versus 1,241 ± 144 mg/kg in the INH and IV groups, respectively. During the last 3-h (305-485 min) the peGIR averaged 7.7 ± 1.1 versus 5.2 ± 1.1 ( Fig. 2B ; p < 0.05), and the peGIR AUCs were 1,547 ± 240 versus 1,054 ± 219 mg/kg during that period in the INH and IV groups, respectively. Thus, the peGIR was greater in the INH compared with the IV group by 48% (3.8 mg/kg/min; p < 0.05) between 35 and 185 min and by 47% (2.5 mg/kg/min; p < 0.05) between 305 and 485 min (Fig. 3 ).
This article has not been copyedited and formatted. The final version may differ from this version. Between 35 and 185 min, net HGU (mg/kg/min) was similar in the two groups (2.5 ± 0.5 versus 2.2 ± 0.6; Fig. 4A ), while (non-HGU was greater (13.6 ± 2.2 versus 10.2 ± 1.3; Fig. 4B ; p < 0.05) in the INH versus IV insulin groups, respectively. Over time, however, a difference in liver glucose uptake began to predominate such that during the last 90 min net HGU was 3.6 ± 0.9 versus 1.8 ± 0.7 (p < 0.05) while non-HGU was 8.4 ± 0.9 versus 7.9 ± 1.3 in the INH versus IV groups. Hepatic glucose fractional extraction was twice as great during the last 90 min in the INH versus the IV group (0.08 ± 0.02 versus 0.04 ± 0.02, respectively; p < 0.05).
To determine if inhalation of insulin affected ACE activity, arterial blood BK, BK1-5, ATI, and ATII were measured (Table 4) . ACE activity leads to degradation of BK into BK1-5 and ATI into ATII; therefore the ratios provide indices of ACE activity.
There were no differences in the arterial levels or ratios of BK1-5 to BK or ATII to ATI.
Furthermore, mean arterial pressure, which is affected by the ACE system, did not differ between groups throughout the study (data not shown).
DISCUSSION
The primary purpose of this study was to determine whether the increase in non-HGU associated with inhalation of insulin is prolonged beyond 4-h. To accomplish this, the arterial plasma insulin kinetics were closely matched in two groups of dogs in which insulin initially entered the blood via pulmonary absorption or via the IVC. Later in the study insulin, was infused in both groups to prevent insulin deficiency. Plasma glucose levels were clamped, and indices of peripheral and hepatic glucose turnover were assessed for 8-h. Inhalation of insulin was associated with increased glucose disposal in In light of these results, one can speculate that the progressive increase of HGU may reflect specific inhaled insulin-dependent transcriptional and translational effects on enzymes that regulate HGU. Also, reciprocity between liver and muscle occurs, so that as liver glucose uptake is enhanced there is a reciprocal decrease in non-HGU such that there is little impact on whole-body glucose disposal (Adkins et al., 1987; Galassetti et al., 1998; Moore et al., 2000) .
In previous studies, circulating insulin levels fell below basal ~3-h after inhalation in the presence of somatostatin (Edgerton et al., 2005; Edgerton et al., 2006) . In the present study we chose to use late infusion of insulin in both groups to prevent insulin This article has not been copyedited and formatted. The final version may differ from this version. deficiency so as to avoid the substantial hyperglycemia which would have occurred over the 8-h duration of the study. In addition, this study design more closely emulates the situation of human patients who do not usually experience complete insulinopenia or marked hyperglycemia overnight. In addition, the glucose lowering effect may be dependant on some minimal insulin presence; for example, if enhancing insulinstimulated glucose transport or slowing deactivation of the insulin receptor is involved.
The Tmax following Exubera inhalation is more rapid in the canine compared to the human (15 vs. 50-60 min) (Becker et al., 2006; Fountaine et al., 2008) . However, when comparing the human data with another, faster-acting inhaled insulin (Technosphere; Tmax 15 min; (Rave et al., 2007) ) the effect on fasting glucose was comparable (personal communication). Therefore, it is not likely that the difference in pharmacokinetics between species is a confounding factor. dependent enhancer of glucose uptake in muscle and fat (Henriksen and Jacob, 2003a; Damas et al., 2004) . Studies also suggest that reduced binding of ATII to the AT 1 receptor may also increase insulin sensitivity (Henriksen et al., 2001) . Although the present study was not designed to specifically test the hypothesis that inhalation of insulin increases glucose utilization by an ACE-dependent effect, ACE activity and arterial blood concentrations of BK, BK1-5, ATI, and ATII were measured. No differential effects of treatment were observed, however, suggesting that the ACE system may not be the mediator of the specific gluco-metabolic effects of inhaled insulin.
It can be hypothesized that decreased fasting glucose levels following insulin inhalation are due to a depot effect stemming from slowly absorbed inhaled insulin.
However, this study, as well as previous studies in humans (Heise et al., 2005) and the dog (Cherrington, et al., 2004; Edgerton et al., 2005; Edgerton et al., 2006b ), indicate that a slow release of insulin from a putative intrapulmonary depot did not occur despite evidence for intrapulmonary accumulation of insulin (Brain et al., 2008) . Given the protracted nature of the effect on glucose disposal, however, we believe that inhaled insulin does generate a long-lived signal in the lungs. The formation of a circulating insulin-sensitizing factor is one possibility, but other mechanisms of action should be considered, for example stimulation of neuronal pathways. This article has not been copyedited and formatted. The final version may differ from this version. 
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